Humira Biosimilars Not Gaining Traction Epitomizes Dysfunctional U.S. System

Impediments to biosimilar access prevent market competition from working properly, raise patient cost-sharing and harm long-term sustainability of biosimilar development.

Source: Forbes.com Healthcare News - December 4, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Senior Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news